Follows adults with atrial fibrillation after heart rhythm catheter ablation
Studies what predicts atrial fibrillation returning after catheter ablation.
Key facts
- Who runs it
- University Hospital, Lille
- Where
- Lille, FranceSee the site
- Trial code
- Registry title
- PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation
- Status
- Recruiting
- People taking part
- 750 people, planned
- Started
- 16 Feb 2023
- Expected to end
- 1 Feb 2031
- Type of study
- Observational
- Treatments tested
- atrial fibrillation catheter ablation
- Record updated
- 22 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who are going to have a catheter ablation for atrial fibrillation. Researchers will follow them to see what predicts the heart rhythm problem coming back.
- Age
- 18 years or older
- Sex
- Men and women
- Disease stage
- Atrial fibrillation, with a catheter ablation planned
Main reasons for not taking part
- Children
- People under guardianship
- People unable to give their consent
- Pregnancy
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patient undergoing atrial fibrillation catheter ablation
- Able to give their consent
Who cannot take part
- Childs
- Patient under guardianship
- Patients unable to give their consent
- Pregnancy
Where in France
- Institut Coeur-Poumon, CHULille, FranceContact: Sandro NINNI, MD (principal investigator)Taking people
About the trial
What the trial wants to find out
Atrial fibrillation ablation is the most common intervention performed worldwide. Up to 20 to 45% of patients show recurrence of AF within 12 month after catheter ablation, however its determinant are incompletely understood.
Read full original descriptionShow less
The aim of the PROSPECT-AF study is to assess the predictors of AF recurrence within the 3 years following ablation using clinical variables and innovative biomarkers in a prospective cohort of 750 patients undergoing atrial fibrillation catheter ablation.
The secondary aims are to assess the incidence of major adverse cardiovascular outcomes (MACE) and the incidence of major bleeding within the 3 years Wolfing catheter ablation.
The group in the trial
- Patients undergoing atrial fibrillation catheter ablation
Patients undergoing scheduled atrial fibrillation catheter ablation.
Treatment: atrial fibrillation catheter ablation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation : LONGITUDINAL STUDY OF PATIENTS UNDERGOING RADIOFREQUENCY ABLATION OF ATRIAL FIBRILLATION.
- Plain-language title
- Follows adults with atrial fibrillation after heart rhythm catheter ablationGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 22 April 2026